Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
Authors:
- Chong-Jen YuCYChong-Jen Yu
- Jin-Yuan ShihJSJin-Yuan Shih
- Chih-Hsin YangCYChih-Hsin Yang
- Pan-Chyr YangPYPan-Chyr Yang
- 1 March 2010
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 67 (3) , 348-354
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancerLung Cancer, 2007
- Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation studyEuropean Respiratory Journal, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995